Obalon Therapeutics Inc (NASDAQ:OBLN) Director Kim P. Kamdar acquired 13,400 shares of the stock in a transaction dated Wednesday, October 12th. The shares were bought at an average price of $15.00 per share, for a total transaction of $201,000.00. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link.
Shares of Obalon Therapeutics Inc (NASDAQ:OBLN) traded up 0.23% during trading on Friday, reaching $13.00. 112,478 shares of the company were exchanged. Obalon Therapeutics Inc has a 1-year low of $12.33 and a 1-year high of $15.88. The stock’s 50 day moving average is $14.47 and its 200 day moving average is $14.47.
About Obalon Therapeutics
Obalon Therapeutics, Inc is a commercial-stage medical device company focused on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. The Company’s product, Obalon balloon system, is a swallowable, gas-filled intragastric balloon designed to provide weight loss in obese patients.
Receive News & Ratings for Obalon Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obalon Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.